Cardinal Health holds steady as investors await a new catalyst.
Cardinal Health (CAH) is a key U.S. healthcare distributor that maintains a steady position as investors await a new company-specific catalyst. The Ohio-based company's scale in pharmaceuticals and medical products, along with its recurring supply flows and execution, are central to its investment case. The article highlights Cardinal Health's role in the U.S. healthcare supply chain and its exposure to prescription volumes and provider purchasing patterns.
Cardinal Health stock hits all-time high at 241.86 USD
Cardinal Health (CAH) stock has reached an all-time high of $241.86, displaying a significant 46.4% total return over the past year. Despite trading near its 52-week high, InvestingPro analysis suggests the stock remains undervalued, highlighting its strong market position and growth trajectory. The company also recently reported Q3 fiscal 2026 earnings, increased its quarterly dividend, and saw notable options trading activity.
Cardinal Health Is More Than a Drug Distributor: Specialty Platforms, Radiopharmaceuticals, and What the Valuation Misses
This article argues that Cardinal Health should be viewed as a scaled healthcare-services platform with specialty and technology-enabled growth areas, rather than just a low-margin drug distributor. It highlights the company's Navista Oncology Network and radiopharmaceutical infrastructure as key differentiators. Investors are advised to focus on specialty growth metrics, Medical segment margin recovery, and capital allocation for a comprehensive valuation.
Cardinal Health focuses on distribution strength amid evolving healthcare demand
Cardinal Health Inc. is leveraging its strong position in pharmaceutical and medical product distribution to meet evolving healthcare demands in the U.S. The company acts as a vital link between manufacturers and providers, benefiting from long-term trends like an aging population and increasing chronic diseases. Its operations involve extensive logistics, inventory management, and a broad product portfolio, ensuring reliable supply and supporting cost efficiencies for healthcare providers.
Cardinal Health strengthens its role in U.S. drug distribution as investors weigh long-term margins
Cardinal Health Inc. is a leading distributor of pharmaceuticals and medical products in the U.S., playing a crucial role in the healthcare supply chain. Investors are focusing on how the company manages distribution growth, maintains margin stability amidst generic drug price fluctuations, and expands its healthcare service offerings. Its business is influenced by prescription drug volumes, generic pricing trends, and U.S. healthcare policies and regulations.
Cardinal Health Kangaroo Joey Enteral Feeding Pump - A long-running workhorse in U.S. hospitals
The article highlights the Cardinal Health Kangaroo Joey Enteral Feeding Pump as a foundational product in U.S. hospitals and home care, valued for its reliability, compact design, and ease of use. It details the pump's features, clinical utility, and role in Cardinal Health's medical segment revenue, emphasizing its "longseller" status due to consistent performance and integration into healthcare workflows. The piece also touches on regulatory compliance, competitive landscape, and the pump's financial significance for Cardinal Health.
Cencora (COR) Could Be 15% Undervalued As Earnings Date Nears
Cencora (COR) is approaching its fiscal third-quarter earnings release on August 5, 2026, with current analysis suggesting it might be undervalued by 15.4%. The company's stock has shown strong long-term performance, and its investments in digital infrastructure are expected to drive higher margins and operating income. However, potential risks include increased regulatory scrutiny on drug pricing and heightened competition in specialty distribution.
Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”
Jim Cramer expressed confidence in Cardinal Health (NYSE: CAH), recommending it to investors and stating that the stock deserves to trade higher despite a recent rotation out of healthcare. He highlighted the company's strong performance in a recent quarter. Cardinal Health supplies branded and generic medicines, and medical products.
Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”
Jim Cramer highlighted Cardinal Health (NYSE: CAH) as a strong stock that deserves to trade higher, despite being obscured by a recent healthcare sector rotation. He emphasized the company's "great quarter" and its position as a "real stalwart." Cramer also mentioned an earlier implosion of the stock that concerned him, but still believes in its potential going forward.
Jim Cramer on Cardinal Health: “It’s Been a Real Stalwart, and I Don’t Think It’s Done”
Jim Cramer expressed confidence in Cardinal Health (NYSE: CAH), recommending it among healthcare stocks that deserve to trade higher. He highlighted its strong performance, despite a recent market rotation out of healthcare, and noted that it is held in his Trust. Cramer believes the stock is a "stalwart" and has further upside potential.
Cardinal Health rated Buy on strong EPS growth and specialty healthcare expansion despite margin risks.
Cardinal Health received a "Buy" rating due to its strong adjusted EPS growth of 35% in Q3FY26, defensive business model, and strategic expansion into specialty healthcare. Despite revenue growth of 11%, GAAP earnings were affected by higher costs. The company's premium valuation and future gains are contingent on maintaining margin improvements and managing risks like opioid litigation.
Is Cardinal Health (CAH) Fully Valued After Its Russell Index Removal?
Cardinal Health (CAH) has been removed from several Russell indices, prompting investors to re-evaluate the stock. Despite a strong share price performance and analysts' valuation indicating it's slightly undervalued, its P/E ratio suggests a higher valuation risk compared to the industry and peers. The article discusses whether its current price reflects demanding future expectations.
Is Cardinal Health (CAH) Fully Valued After Its Russell Index Removal?
Cardinal Health (CAH) was removed from several Russell indices following strong share price performance, leading investors to re-evaluate the stock. While Simply Wall St's narrative suggests it's slightly undervalued at $245.27, its P/E ratio of 36x is higher than the industry average, signaling potential valuation risk. Investors are encouraged to assess the full picture of the company's rewards and risks.
MCK - Mckesson Corp Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for McKesson Corp (MCK). It includes current stock performance metrics, valuation ratios, dividend information, and insider and institutional ownership percentages, alongside various profitability and efficiency ratios.
Enterprise value to revenue forward of Cardinal Health, Inc. – NYSE:CAH
This article provides financial data for Cardinal Health, Inc. (NYSE: CAH), specifically focusing on its enterprise value to revenue forward. It appears to be a financial snapshot from TradingView, including market information and links to various financial tools and community features.
Enterprise value to revenue forward of Cardinal Health, Inc. – MIL:1CAH
The article provides the enterprise value to revenue forward for Cardinal Health, Inc. (MIL:1CAH). It appears to be a financial data point from TradingView, offering a quick snapshot of a valuation metric for the company.
Cardinal Health, Inc. Stock 12‑Month Price Target Raised to $248.27, Implies 4% Upside
The average 12-month price target for Cardinal Health, Inc. (CAH) stock has increased to $248.27 from $246.93, based on estimates from 15 analysts. This updated target suggests a potential 4% upside from the July 1 closing price. The consensus rating for CAH remains a "Buy" from 21 analysts.
Price to sales forward of Cardinal Health, Inc. – NYSE:CAH
This article briefly mentions the "Price to sales forward" metric for Cardinal Health, Inc. (NYSE: CAH). The content appears to be a stub or preview from a financial data platform, providing basic company information and navigation links without detailed financial analysis.
AI Models Split on Cardinal Health (CAH) as Balance Sheet Risk Offsets Strong Earnings
AI models are split on Cardinal Health (CAH) due to differing weights given to its strong earnings and cash flow versus its balance sheet risk and technical weakness. One bullish model highlights exceptional earnings momentum and raised guidance, while a more cautious model emphasizes concerns about leverage and short-term technical signals. This divergence suggests that the investment case for CAH depends on an investor's comfort with risk and tolerance for volatility.
Cencora CubixxCT from Cencora Inc. - cold-chain automation for hospital pharmacies
Cencora has introduced CubixxCT, an RFID-enabled, temperature-controlled inventory management system for hospital and specialty pharmacy cold chains in the US. This system automates the tracking of high-value biologic drugs and vaccines, improving compliance, reducing waste, and integrating into existing clinical workflows. It represents Cencora's strategic move into service-based revenue beyond commodity drug wholesaling.
Cardinal Health opens the week with analyst focus, shares in S&P 500 healthcare
Cardinal Health is starting the week with significant attention from analysts due to its role as a major U.S. healthcare distributor and its inclusion in the S&P 500. Analysts are particularly focused on its operating margin trends, cash generation, and capital returns, balancing pressures from generic drug prices with opportunities in specialty pharmaceuticals. The company's performance and consensus estimates are closely watched by investors, especially concerning its impact on ETF flows and index-tracking strategies.
The Kangaroo ePump Enteral Feeding Pump from Cardinal Health Inc. - quiet bedside workhorse with pre
The article describes the Kangaroo ePump Enteral Feeding Pump from Cardinal Health Inc., highlighting its features such as programmable low-noise feeding, automatic flushing, and detailed history logs for hospital and home care. It emphasizes the pump's user-friendly design for nursing staff, its safety features, and its position as a key product within Cardinal Health's medical portfolio. Despite minor user frustrations with button responsiveness and display, the ePump remains a reliable device for enteral nutrition.
Cardinal Health, Inc.(NYSE: CAH) dropped from Russell 1000 Growth-Defensive Index
Cardinal Health, Inc. (NYSE: CAH) has been removed from the Russell 1000 Growth-Defensive Index, as announced on June 29, 2026. This news follows several other recent updates for the company, including analyst ratings, funding announcements, and dividend declarations. The company specializes in the distribution of pharmaceutical and medical products.
Is McKesson Corporation (MCK) A Good Stock To Buy Now?
This article summarizes a bullish thesis on McKesson Corporation (MCK), arguing that its recent stock decline presents an attractive buying opportunity. The thesis highlights McKesson's dominant position in pharmaceutical distribution, its asset-light business model generating significant cash flow, and its strategic shift towards higher-margin businesses. Despite a recent revenue miss, the company's core investment thesis remains intact, with conservative estimates suggesting 18% upside and more realistic scenarios pointing to 70% upside.
Cardinal Health opens the week with earnings calendar, shares steady
Cardinal Health Inc (US14149Y1082) begins the week with its next earnings date as the primary focus for investors. The company, which trades on the NYSE, is a key player in the U.S. health care distribution sector, providing pharmaceuticals and medical products. Its business model relies on volume, pricing discipline, and logistics efficiency in a broad market.
Enterprise value to EBIT forward of Cardinal Health, Inc. – NYSE:CAH
This article provides the enterprise value to EBIT forward for Cardinal Health, Inc. (NYSE: CAH). It presents this financial metric within the context of TradingView's platform, offering financial data for the company. The page structure includes typical navigation for market data, news, and community features but focuses on the specified financial value for CAH.
Cardinal Health opens the week with strong momentum, shares extend sector outperformance
Cardinal Health (US14149Y1082) started the week with strong performance, showing a significant one-month gain compared to the broader medical sector and the S&P 500. The prescription drug distributor's shares closed at $237.92, up 1.35% for the day and 17.46% over the last month. This outperformance highlights investor expectations for stable cash flows from long-term supply contracts.
Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh
This page provides financial overview information for Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh (C1AH34) on the B3 exchange. It currently shows no trades as the market is closed, and includes sections for financials, news, community insights, technical analysis, and forecasts. The core focus is on the "Price to earnings forward" metric for this specific stock.
Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh
This article provides access to the Price to Sales Forward data for Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh (C1AH34) on the BMFBOVESPA via TradingView. It highlights the stock's financial overview and confirms that the market is currently closed with no trades. The content serves as a portal to financial data and tools within the TradingView platform for the specified security.
Enterprise value to EBITDA forward of Cardinal Health, Inc. – NYSE:CAH
This article provides financial information for Cardinal Health, Inc. (NYSE: CAH), specifically focusing on its enterprise value to EBITDA forward metric. It indicates that the period value and changes for this metric are presented, noting the information is generated by human analysis and derived from various financial data providers.
Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh
This page provides financial information for Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh (C1AH34) on the B3 exchange, specifically focusing on its Enterprise Value to EBITDA (forward-looking). The market for this instrument was closed, with no trades reported.
Henry Schein focuses on long-term strategy, shares in a defensive health peer group
Henry Schein maintains its position as a mid-cap leader in U.S. healthcare distribution, aligning with defensive healthcare peers due to its long-term strategy. The company focuses on dental, medical, and animal health products for small to mid-sized practitioners, generating over $10 billion in annual revenue. This strategy provides stability and consistent cash flow, distinguishing it from hospital-focused wholesalers while attracting institutional investors seeking defensive sector holdings.
Sureties SureStep Podiatry Instruments from Cardinal Health Inc. - single-use focus in foot care
Cardinal Health's Sureties SureStep Podiatry Instruments are single-use kits designed for routine foot procedures, offering standardization and hygiene benefits for clinics and podiatrists. While they reduce cross-contamination risk and streamline workflows, the trade-off is increased waste. These instruments are part of Cardinal Health's broader medical products portfolio, contributing to recurring revenue streams and supporting the company's stock value.
Cardinal Health charts a technical range, shares sit between key support and resistance
Cardinal Health's shares are currently trading within a defined technical range on the NYSE, positioned between established support and resistance levels. The company, a major healthcare distributor, recently reported positive gains after an earnings beat and guidance raise, and shows a constructive technical stance with multiple buy signals according to TradingKey analysis. Despite a conservative valuation and modest dividend yield, the company benefits from a strong bottom-line discipline and exposure to growing markets like neonatal intensive care respiratory devices.
States seek to lower drug prices by targeting the companies that manage them for health plans
States across the U.S. are increasingly targeting pharmacy benefit managers (PBMs) to lower prescription drug costs amid consumer concerns about affordability. Legislators in multiple states have passed laws to limit PBM compensation, set minimum pharmacist payments, and increase disclosure requirements, with some measures facing legal challenges from PBMs like CVS Health. While PBMs claim they help reduce drug costs, critics argue they contribute to high prices and squeeze independent pharmacies, leading to a complex debate with federal regulatory efforts also underway.
States seek to lower drug prices by targeting the companies that manage them for health plans
States are increasingly attempting to regulate pharmacy benefit managers (PBMs) to lower prescription drug costs for consumers. Several states passed laws this year to limit PBM compensation, set minimum payments to pharmacists, and demand more transparency, with CVS Health Corp. actively fighting these new regulations. The debate highlights the tension between large PBMs, independent pharmacies, and worried consumers concerned about medication accessibility and affordability.
Cardinal Health (CAH) Is Up 7.3% After EPS Beat And Neonatal Respiratory Tailwind News - What's Changed
Cardinal Health (CAH) saw its stock rise by 7.3% after reporting an EPS beat and benefiting from positive news regarding the expanding neonatal intensive care respiratory devices market, projected to reach US$5.70 billion by 2035. This performance reinforces investor confidence in Cardinal Health's healthcare distribution and products platform, despite long-term concerns about margin pressure from regulation and competition. The company's continued share repurchases and focus on growth areas are key aspects of its investment narrative.
Why the Market Dipped But Cardinal Health (CAH) Gained Today
Cardinal Health (CAH) stock saw a 1.35% increase, outperforming the broader market which experienced a dip. The company's stock has climbed 17.46% over the past month, exceeding its sector and the S&P 500, with strong forecasted earnings and revenue growth. Cardinal Health currently holds a Zacks Rank of #2 (Buy) and trades at a premium compared to its industry's average Forward P/E ratio.
Cardinal Health Inc. stock underperforms Friday when compared to competitors despite daily gains
Shares of Cardinal Health Inc. (CAH) rose 1.35% on Friday, marking its fifth consecutive day of gains, despite an overall grim trading session for the stock market. However, the stock underperformed compared to its competitors. The S&P 500 Index fell 0.05% and the Dow Jones Industrial Average dropped 0.09%.
What Cardinal Health (CAH) Guidance Raise Means For Valuation
Cardinal Health (CAH) recently reported strong fiscal third-quarter earnings and raised its earnings outlook, driven by its focus on specialty and radiopharmaceuticals. While the company's stock shows significant momentum and is considered modestly undervalued with a fair value of $245.27, its P/E ratio of 34.5x is higher than the industry average, suggesting a premium that could limit future upside. Investors should consider the balance of optimism and concerns regarding government pricing scrutiny and potential reimbursement changes.
Cardinal Health hits fresh high, shares ride strong health care momentum
Cardinal Health's shares have reached a new record high, benefiting from a strong rally in U.S. health care stocks. The company, a major distributor of pharmaceuticals and medical supplies, saw its stock gain about 20% over the past four weeks. Analysts note continued investor interest, with the company's fiscal third-quarter earnings exceeding estimates.
How Truist’s Support and Governance Votes At AdaptHealth (AHCO) Have Changed Its Investment Story
Truist Securities reiterated its positive stance on AdaptHealth (AHCO) after recent meetings with management, reinforcing confidence in its governance and leadership following the 2026 annual stockholder meeting. While boosting sentiment, this commentary doesn't fundamentally alter the core investment narrative, which still focuses on achieving revenue guidance, improving margins, and successful acquisition integration. Investors should monitor ongoing losses, execution risks in acquisitions, and the use of the new credit facility.
Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh
This page provides financial actuals and estimates for Cardinal Health, Inc. Unsponsored Brazilian Depositary Receipt Repr 1 Sh (BMFBOVESPA:C1AH34). Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time, while noting that the information is not investment advice.
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
This article compares AbbVie and Pfizer as investment options for 2026, focusing on their post-pandemic growth strategies, drug pipelines, and financial health. While both pharma giants face patent expirations and debt, AbbVie is highlighted for its near-term success with new immunology products and acquisitions, giving it an edge over Pfizer which relies more on potential future approvals and GLP-1 developments. The analysis includes financial metrics, risk profiles, and valuation metrics, concluding that AbbVie is the better buy for 2026.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
Cardinal Health (CAH) recently hit a new 52-week stock high, outperforming the medical sector and dental supplies industry with strong earnings surprises. The company boasts favorable valuation metrics, including an "A" VGM Score and a Zacks Rank of #2 (Buy), suggesting potential for further growth. Another industry peer, Align Technology (ALGN), also shows strong performance and a "Buy" rank.
Cardinal Health clears a fresh record, shares extend the strong run on NYSE
Cardinal Health (CAH) shares have reached a new all-time high on the NYSE, trading between $233 and $235. This surge is attributed to strong fiscal Q3 2026 earnings, where adjusted EPS surpassed expectations, and a raised quarterly dividend. Technical indicators also show a strong buy signal, with the stock trading well above its 50-day and 200-day moving averages.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
Cardinal Health (CAH) recently reached a new 52-week high, with its stock up 16.6% over the past month and 13.4% year-to-date, outperforming the Zacks Medical sector. The company has a strong record of positive earnings surprises and favorable valuation metrics, holding a Zacks Rank #2 (Buy). Analysts suggest that given its strong fundamentals and positive industry tailwinds, CAH may still have room for further growth.
Cardinal Health (CAH) Ascends While Market Falls: Some Facts to Note
Cardinal Health (CAH) closed up +1.79% while the S&P 500 fell, and its shares have gained 14.24% over the past month. The company is expected to report an EPS of $2.41, a 15.87% increase, and revenue of $65.61 billion, up 9.06%. CAH currently holds a Zacks Rank of #3 (Hold) and is trading at a Forward P/E of 21.27, a premium to its industry average.
Cardinal Health Inc. stock outperforms competitors on strong trading day
Cardinal Health Inc. (CAH) stock rose 1.79% to $233.01 on Wednesday, outperforming the S&P 500 Index despite a mixed trading day for the broader market. This marks the third consecutive day of gains for the company's stock. The Dow Jones Industrial Average also saw a modest increase.
What Cardinal Health (CAH) Guidance Raise Means For Valuation
Cardinal Health (CAH) recently reported strong fiscal third-quarter earnings and raised its outlook, driven by its focus on specialty pharmaceuticals. While the company's shares have shown significant momentum and are trading at an intrinsic discount, its current P/E ratio suggests investors may be paying a premium. This article explores the valuation implications, presenting both an "undervalued" narrative and a word of caution based on earnings multiples.
